Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010807 | 1.00 | SLC18A3 (0.43) | SLC18A3FUCA1CCR5JAK2JAK1 | |
| SCHEMBL22605146 | 1.00 | SLC18A3 (0.43) | SLC18A3FUCA1CCR5JAK2JAK1 | |
| SCHEMBL6785103 | 0.86 | NR1H2 (0.47) | FUCA1JAK2JAK1GPR119STS | |
| SCHEMBL16064467 | 0.85 | CCR5 (0.52) | CCR5JAK2JAK1GPR119STS | |
| SCHEMBL18495417 | 0.85 | CCR5 (0.52) | CCR5JAK2JAK1GPR119STS | |
| SCHEMBL1984795 | 0.81 | AGTR2 (0.48) | CCR5JAK2JAK1GPR119KMT2A | |
| SCHEMBL2381394 | 0.81 | AGTR2 (0.48) | CCR5JAK2JAK1GPR119KMT2A | |
| SCHEMBL1983287 | 0.81 | AGTR2 (0.48) | CCR5JAK2JAK1GPR119KMT2A | |
| SCHEMBL18599553 | 0.80 | NR1H2 (0.46) | CCR5JAK2JAK1GPR119KMT2A | |
| SCHEMBL993829 | 0.80 | CCR5 (0.58) | SLC18A3CCR5JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662203-B2 | Pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, KYNU | SLC18A3 2647/4885FUCA1 3761/4885CCR5 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.